Centessa Pharmaceuticals plc announced the appointment of April Dovholuk and Ellie Im, MD to Centessa's executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa's global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company's Oncology programs based on the LockBody technology platform. Ms. Dovholuk is an experienced global operational leader.

Prior to joining Centessa, Ms. Dovholuk was Senior Vice President, Clinical Development Operations at Replimune where she led teams in clinical operations, data management, process improvement and CRO management. Ms. Dovholuk also spent 10 years with Takeda Oncology in various clinical operations roles supporting development operations and managing multiple assets throughout the drug development process. Ms. Dovholuk holds a BS from Cornell University.

Dr. Im is an experienced drug developer and leader. She most recently served as Senior Vice President, Clinical Development and Operations at Mersana Therapeutics Inc. Previously, Dr. Im was Clinical Development Lead and Senior Medical Director at Tesaro Inc., an oncology-focused company that was later acquired by GlaxoSmithKline plc. She also served as Medical Director for Merck Co, Oncology Clinical Development where she was medical lead for the KEYNOTE-010 and -021 studies.

Dr. Im is a medical oncologist and holds an MD from Catholic University College of Medicine, South Korea. She is Board certified in Internal Medicine and Medical Oncology and a member of the American Society of Clinical Oncology and Hematology.